Corrigendum: Selective inhibition of EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti-tumor activity in breast cancer

Scientific Reports 6: Article number: 2086410.1038/srep20864; Published online: February122016; Updated: April292016

This Article contains typographical errors.

In the Results section under subheading ‘Impact of ZLD1039 on breast cancer cell growth’,

“Among the cell lines, MCF-7 and ZR-75-1 were the most sensitive to ZLD1039 with IC₅₀ values of 0.99 ± 0.23 and 0.089 ± 0.019 μM, respectively”.

should read:

“Among the cell lines, MCF-7 and ZR-75-1 were the most sensitive to ZLD1039 with IC₅₀ values of 0.99 ± 0.23 and 1.089 ± 0.019 μM, respectively”.

In Figure 3d, the x-axis ‘1–8 days of treatment’ was incorrectly given as ‘0–7 days of treatment’. The correct Figure 3d appears below as Fig. 1

Figure 1.